Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. Steinman L, Fox E, Hartung HP, Alvarez E, et al. N Engl J Med 2022;387:704-714.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Steinman L, Fox E, Hartung HP, Alvarez E, et al. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med 2022;387:704-714.
PMID: 36001711